Article Text

Download PDFPDF
Original article
Prevention of recurrent idiopathic gastroduodenal ulcer bleeding: a double-blind, randomised trial

Footnotes

  • Contributors GL-HL-HW, JYLC and FKLC were responsible for the conception, design of the study and the development of methodology. GL-HL-HW, LHSL, JYLC, RHYL, VW-SW, PWYC, JL and FKLC were responsible for patient care, data collection and analysis. GL-HL-HW, LHSL, JYLC, YKT and RHYL were responsible for data analysis. All authors were responsible for the interpretation of data, writing, review and final approval of the manuscript. All authors had access to the study data.

  • Funding This study was funded in part by the General Research Fund – Research Grant Council (project reference number: 477213) to GL-HL-HW.

  • Competing interests GL-HL-HW has served as a speaker for Abbott, AbbVie, Bristol-Myers Squibb, Echosens, Gilead and Janssen, and an advisory committee member for Gilead and Janssen. VW-SW has served as a speaker for AbbVie, Bristol-Myers Squibb, Roche, Novartis, Abbott Diagnostics and Echosens, and an advisory committee member for AbbVie, Roche, Novartis, Gilead and Otsuka. PWYC has served as a speaker for Olympus and an advisory committee member for EndoMASTER and Aptorum. JL has served as a speaker for Boston Scientific. FKLC has served as a consultant to Eisai, Pfizer, Takeda and Otsuka, and has been paid lecture fees by Eisai, Pfizer, AstraZeneca and Takeda.

  • Ethics approval The study was done in compliance with the principles of Good Clinical Practice and the Declaration of Helsinki. The local ethics committee approved the study protocol. All patients gave written informed consent.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Patient consent for publication Obtained.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors GL-HL-HW, JYLC and FKLC were responsible for the conception, design of the study and the development of methodology. GL-HL-HW, LHSL, JYLC, RHYL, VW-SW, PWYC, JL and FKLC were responsible for patient care, data collection and analysis. GL-HL-HW, LHSL, JYLC, YKT and RHYL were responsible for data analysis. All authors were responsible for the interpretation of data, writing, review and final approval of the manuscript. All authors had access to the study data.

  • Funding This study was funded in part by the General Research Fund – Research Grant Council (project reference number: 477213) to GL-HL-HW.

  • Competing interests GL-HL-HW has served as a speaker for Abbott, AbbVie, Bristol-Myers Squibb, Echosens, Gilead and Janssen, and an advisory committee member for Gilead and Janssen. VW-SW has served as a speaker for AbbVie, Bristol-Myers Squibb, Roche, Novartis, Abbott Diagnostics and Echosens, and an advisory committee member for AbbVie, Roche, Novartis, Gilead and Otsuka. PWYC has served as a speaker for Olympus and an advisory committee member for EndoMASTER and Aptorum. JL has served as a speaker for Boston Scientific. FKLC has served as a consultant to Eisai, Pfizer, Takeda and Otsuka, and has been paid lecture fees by Eisai, Pfizer, AstraZeneca and Takeda.

  • Ethics approval The study was done in compliance with the principles of Good Clinical Practice and the Declaration of Helsinki. The local ethics committee approved the study protocol. All patients gave written informed consent.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Patient consent for publication Obtained.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.